What is it about?
TM is an ideal treatment for patients with DIC based upon hematologic malignancy.
Featured Image
Why is it important?
Coagulation tests were significantly improved after TM treatment even in subjects whose clinical course of underlying disease was assessed as unchanged or exacerbated.
Read the Original
This page is a summary of: Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation - Safety and efficacy in 1,032 patients with hematologic malignancy, Thrombosis Research, March 2014, Elsevier,
DOI: 10.1016/j.thromres.2013.12.033.
You can read the full text:
Resources
Contributors
The following have contributed to this page
